A Phase 2 Multicenter Open-label Study Evaluating the Safety and Efficacy of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer (CRPC) and a Rising Prostate-specific Antigen (PSA).

Trial Profile

A Phase 2 Multicenter Open-label Study Evaluating the Safety and Efficacy of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer (CRPC) and a Rising Prostate-specific Antigen (PSA).

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2014

At a glance

  • Drugs Orteronel (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Jan 2013 Planned End Date changed from 1 May 2015 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Results were reported at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO), according to a Millennium media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top